Syra Health Posts $2.56M in Q3 Revenue, Topping Last Quarter's $2.4M
SYRA has more than doubled off its 52-week low of $0.056 on elevated volume (2.4× avg).
Summary
Syra Health reported third-quarter revenue of $2.56M, up from the $2.4M it booked in Q2, a 52% rise. Net income for the quarter was $344.6K, or EPS of 2c, extending the top-line trend after the company posted net income of $250,242 in Q2, its second straight profitable quarter. Scale matters here: this is a micro-cap OTC name, and the Q2 filing warned it may lack the cash to survive the next 12 months without raising more money, which keeps dilution risk in play after the September S-1 covering 3.17 million warrant shares. Watch the full Q3 release for cash balance.
At the time of this announcement, SYRA was trading at $0.93 on OTC in the Life Sciences sector, with a market capitalization of approximately $13.2M. The 52-week trading range was $0.06 to $1.15. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.